Exploring the Latest Advances in the Treatment of Diabetic E -

Media formats available:

Details

Presenters

Overview
Join Program Chair Nancy M. Holekamp, MD, and fellow retina specialists Sunir J. Garg, MD, FACS, FASRS, and Jennifer I. Lim, MD, for this live-virtual symposium. The panel of experts will discuss the available armamentarium and how those treatments have impacted their patients with diabetic eye disease. The faculty will also review data on newly approved and pipeline therapies and examine which patients could most benefit from these cutting-edge treatments.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Discuss current and future therapeutic agents for diabetic eye disease and the implications for patient outcomes
- Identify patients who may benefit from the next generation of retinal disease therapies
- Develop strategies to improve adoption of cutting-edge therapies for the treatment of diabetic eye diseases into clinical practice
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Nancy M. Holekamp, MD
Director, Retina Services
Pepose Vision Institute
Chesterfield, MO

Sunir J. Garg, MD, FACS, FASRS
Professor of Ophthalmology
Thomas Jefferson University and Wills Eye Retina Service
Co-Director of Retina Research and Partner
Mid Atlantic Retina
Philadelphia, PA

Jennifer I. Lim, MD
Marion H. Schenk Chair in Ophthalmology
Professor of Ophthalmology
Vice-Chair for Diversity & Inclusion
Director of the Retina Service
University of Illinois at Chicago
Chicago, IL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Nancy M. Holekamp, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint Pharmaceuticals, Gemini Therapeutics, Gyroscope, Katalyst Surgical, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron Pharmaceuticals, Stealth Biosciences, and Thea Laboratoires. Grant/Research Support: Gemini Therapeutics, Genentech, Gyroscope, and Notal Vision. Speaker’s Bureau: Allergan, Apellis, Genentech, Regeneron Pharmaceuticals, and Spark Therapeutics. Stock/Shareholder: Gemini Therapeutics, Katalyst Surgical, and Nacuity.
Sunir J. Garg, MD, FACS, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, American Academy of Ophthalmology, Apellis Pharmaceuticals, Bausch + Lomb, Boehringer Ingelheim, Kanaph Therapeutics, and Merck Manual. Grant/Research Support: American Academy of Ophthalmology, Apellis Pharmaceuticals, Boehringer Ingelheim, Genentech, NGM Biopharmaceuticals, and Regeneron Pharmaceuticals. Advisory Board: Coherus BioSciences.
Jennifer I. Lim, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Aura Bioscience, Cognition, Genentech, Iveric Bio, Luxa, Novartis, Ophthea, Quark, Santen, Unity, and Viridian. Grant/Research Support: Alderya, Chengdu Kanghong Biotechnology, Graybug, NGM, Regeneron Pharmaceuticals, and Stealth.
The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/08/2022